Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity

Transplantation

Volumn 83, Issue 5, 2007, Pages 631-640

  Durakovic, Nadira ^a   Radojcic, Vedran ^a   Powell, Jonathan ^a   Luznik, Leo ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Cancer Research Building ^*  (United States)

Author keywords

Donor lymphocyte infusions; Graft versus leukemia; Pharmacologic immunosuppression; Rapamycin

Indexed keywords

INTERLEUKIN 10; RAPAMYCIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL SECRETION; CELL TRANSFER; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOREGULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANIMALS; CELL DIFFERENTIATION; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELLS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED STRAINS; MODELS, ANIMAL; SIROLIMUS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 33947316577     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000256158.84418.ff     Document Type: Article

References (51)

1. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]. Blood 1995; 86: 2041.
2. Kolb HJ, Schmid C, Barrett AJ, et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767.
3. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261.
4. Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002; 9: 123.
5. Akpek G, Boitnott JK, Lee LA, et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood 2002; 100: 3903.
6. de Lima M, Bonamino M, Vasconcelos Z, et al. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant 2001; 27: 73.
7. Levine JE, Braun T, Penza SL, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405.
8. Luznik L, Jalla S, Engstrom LW, et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 2001; 98: 3456.
9. Mapara MY, Kim Y-M, Marx J, et al. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism. Transplantation 2003; 76: 297.
10. Bierer BE, Mattila PS, Standaert RF, et al. Two distinct signal transmission pathways in t lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci USA 1990; 87: 9231.
11. Dumont FJ, Staruch MJ, Koprak SL, et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990; 144: 251.
12. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14: 483.
13. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35 (3 Suppl): 7S.
14. Li Y, Li X, Zheng X, et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 1298.
15. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces t cell clonal anergy even in the presence of costimulation. J Immunol 1999; 162: 2775.
16. Ferraresso M, Tian L, Ghobrial R, et al. Rapamycin inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate long-term survival of heart allografts in rats. J Immunol 1994; 153: 3307.
17. Foley JE, Jung U, Miera A, et al. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J Immunol 2005; 175: 5732.
18. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, et al. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. J Immunol 1998; 160: 5355.
19. Tian L, Lu L, Yuan Z, et al. Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery1. Transplantation 2004; 77: 183.
20. Sykes M, Sheard MA, Sachs DH. Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med 1988; 168: 2391.
21. Mapara MY, Kim Y-M, Wang S-P, et al. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002; 100: 1903.
22. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994; 171: 131.
23. Blazar BR, Taylor PA, Sehgal SN, et al. Rapamycin prolongs survival of murine recipients of fully allogeneic donor grafts when administered during the graft-versus-host disease process. Ann NY Acad Sci 1993; 685: 73.
24. Broeren CPM, Gray GS, Carreno BM, et al. Costimulation light: activation of CD4+ T cells with CD80 or CD86 rather than anti-CD28 leads to a Th2 cytokine profile. J Immunol 2000; 165: 6908.
25. Yang Y-G, Qi J, Wang M-G, et al. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. Blood 2002; 99: 4207.
26. Slavik JM, Lim D-G, Burakoff SJ, et al. Uncoupling p70s6 kinase activation and proliferation: rapamycin-resistant proliferation of human CD8+ T lymphocytes. J Immunol 2001; 166: 3201.
27. Chen B, Morris R, Chao N. Graft-versus-host disease prevention by rapamycin: cellular mechanisms. Biol Blood Marrow Transplant 2000; 6: 529.
28. Bacchetta R, Bigler M, Touraine JL, et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 1994; 179: 493.
29. Wing K, Fehervari Z, Sakaguchi S. Emerging possibilities in the development and function of regulatory T cells. Int Immunol 2006; 18: 991.
30. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199.
31. O'Garra A, Vieira PL, Vieira P, et al. IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. J Clin Invest 2004; 114: 1372.
32. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330.
33. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057.
34. Khattri R, Cox T, Yasayko SA, et al. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003; 4: 337.
35. Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696.
36. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23(9): 1993.
37. Truitt RL, Atasoylu AA. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation. Blood 1991; 77: 2515.
38. Blazar BR, Taylor PA, Boyer MW, et al. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed postbone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J Immunol 1997; 159: 3460.
39. Durakovic N, Bezak KB, Skarica M, et al. Host-derived langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions. J Immunol 2006; 177: 4414.
40. Tanchot C, Barber DL, Chiodetti L, et al. Adaptive TOLERANCE of CD4+ T cells in vivo: multiple thresholds in response to a constant level of antigen presentation. J Immunol 2001; 167: 2030.
41. Tanchot C, Guillaume S, Delon J, et al. Modifications of CD8+ T cell function during in vivo memory or tolerance induction. Immunity 1998; 8: 581.
42. Spaner D, Sheng-Tanner X, Raju K, et al. Long-term persistence of IL-2-unresponsive allogeneic T cells in sublethally irradiated SCID mice. Int Immunol 1999; 11: 1601.
43. Hara M, Kingsley CI, Niimi M, et al. IL-10 Is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166: 3789.
44. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737.
45. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, et al. CD25+ CD4+T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 2001; 166: 3008.
46. Asseman C, Mauze S, Leach MW, et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190: 995.
47. Barrat FJ, Cua DJ, Boonstra A, et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002; 195: 603.
48. Suri-Payer E, Cantor H. Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4+CD25+T cells. J Autoimmun 2001; 16: 115.
49. Bacchetta R, Parkman R, McMahon M, et al. Dysfunctional cytokine production by host-reactive T-cell clones isolated from a chimeric severe combined immunodeficiency patient transplanted with haploidentical bone marrow. Blood 1995; 85: 1944.
50. Battaglia M, Stabilini A, Roncarolo M-G. Rapamycin selectively expands CD4+CD25+FOXP3+ regulatory T cells. Blood 2005; 105: 4743.
51. Battaglia M, Stabilini A, Draghici E, et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 2006; 55: 40.